U.S. markets close in 2 hours 14 minutes
  • S&P 500

    3,900.25
    -1.57 (-0.04%)
     
  • Dow 30

    31,575.13
    +39.62 (+0.13%)
     
  • Nasdaq

    13,502.26
    -86.57 (-0.64%)
     
  • Russell 2000

    2,251.16
    -24.16 (-1.06%)
     
  • Crude Oil

    60.66
    +0.02 (+0.03%)
     
  • Gold

    1,736.00
    +13.00 (+0.75%)
     
  • Silver

    26.95
    +0.28 (+1.04%)
     
  • EUR/USD

    1.2090
    +0.0031 (+0.25%)
     
  • 10-Yr Bond

    1.4210
    -0.0250 (-1.73%)
     
  • GBP/USD

    1.3975
    +0.0055 (+0.39%)
     
  • USD/JPY

    106.7300
    0.0000 (0.00%)
     
  • BTC-USD

    47,733.66
    -1,059.54 (-2.17%)
     
  • CMC Crypto 200

    956.78
    -29.87 (-3.03%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Lyndra Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

·1 min read

Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past with the first-ever ultra-long-acting, sustained release oral therapies, today announced that members of its management team will participate in the SVB Leerink 10th Annual Global Healthcare Conference being held virtually February 22-26, 2021.

About Lyndra Therapeutics

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company’s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra’s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH. For more information, visit the Company’s website at www.lyndra.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005397/en/

Contacts

Media
Cammy Duong
Westwicke, an ICR company
cammy.duong@westwicke.com
203-682-8380

Investors
Christopher Brinzey
Westwicke, an ICR company
chris.brinzey@westwicke.com
339-970-2843